Please login to the form below

Not currently logged in
Email:
Password:

gefitinib

This page shows the latest gefitinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer closes on EU approval of lung cancer drug Vizimpro

Pfizer closes on EU approval of lung cancer drug Vizimpro

Pfizer persisted with a third study that showed Vizimpro was able to extend progression-free survival (PFS) compared to AZ’s first-generation EGFR inhibitor Iressa (gefitinib).

Latest news

More from news
Approximately 1 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    It is a particularly pressing matter for AZ considering the company has several personalised medicines on market or in development, including Iressa (gefitinib) to treat lung cancer patients with a mutation

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and Iressa (gefitinib), an epidermal growth factor receptor tyrosine kinase

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics